Hina Jayantilal Shah, M.B.,B.S.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Radiopharmaceuticals | 8 | 2024 | 2703 | 1.080 |
Why?
|
| Technetium Tc 99m Pyrophosphate | 1 | 2024 | 52 | 0.890 |
Why?
|
| Lutetium | 2 | 2023 | 38 | 0.880 |
Why?
|
| Gallbladder | 1 | 2024 | 308 | 0.790 |
Why?
|
| Receptors, Somatostatin | 1 | 2022 | 138 | 0.720 |
Why?
|
| Nuclear Medicine | 1 | 2024 | 262 | 0.700 |
Why?
|
| Gastric Emptying | 1 | 2022 | 247 | 0.690 |
Why?
|
| Mouth Neoplasms | 2 | 2022 | 597 | 0.660 |
Why?
|
| Epidermal Cyst | 1 | 2014 | 63 | 0.430 |
Why?
|
| Pineal Gland | 1 | 2014 | 158 | 0.420 |
Why?
|
| Fluorodeoxyglucose F18 | 5 | 2024 | 2028 | 0.400 |
Why?
|
| Thyroid Neoplasms | 1 | 2024 | 2355 | 0.350 |
Why?
|
| Lymph Nodes | 1 | 2022 | 3468 | 0.340 |
Why?
|
| Positron-Emission Tomography | 6 | 2022 | 6548 | 0.330 |
Why?
|
| Radionuclide Imaging | 2 | 2022 | 1986 | 0.290 |
Why?
|
| Head and Neck Neoplasms | 1 | 2022 | 2930 | 0.280 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2017 | 1433 | 0.270 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2014 | 1374 | 0.260 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2022 | 4050 | 0.260 |
Why?
|
| Brain Diseases | 1 | 2014 | 1552 | 0.240 |
Why?
|
| Alpha Particles | 1 | 2024 | 29 | 0.230 |
Why?
|
| Dipeptides | 2 | 2023 | 386 | 0.220 |
Why?
|
| Prostate-Specific Antigen | 2 | 2023 | 2463 | 0.210 |
Why?
|
| Receptors, Peptide | 1 | 2024 | 280 | 0.200 |
Why?
|
| Angiomyolipoma | 1 | 2024 | 189 | 0.200 |
Why?
|
| Axilla | 2 | 2022 | 622 | 0.190 |
Why?
|
| Adrenocortical Carcinoma | 1 | 2022 | 88 | 0.190 |
Why?
|
| Adrenal Cortex Neoplasms | 1 | 2022 | 161 | 0.180 |
Why?
|
| Urea | 1 | 2023 | 449 | 0.180 |
Why?
|
| Prostatic Neoplasms | 1 | 2023 | 11094 | 0.170 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2022 | 638 | 0.170 |
Why?
|
| Taxoids | 1 | 2022 | 665 | 0.160 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2024 | 454 | 0.160 |
Why?
|
| Mutagenesis | 1 | 2022 | 1228 | 0.150 |
Why?
|
| Lysine | 1 | 2023 | 998 | 0.150 |
Why?
|
| Neoplasms | 3 | 2022 | 22350 | 0.150 |
Why?
|
| Spleen | 1 | 2024 | 2295 | 0.150 |
Why?
|
| Abdomen | 1 | 2024 | 1137 | 0.150 |
Why?
|
| Neuroendocrine Tumors | 1 | 2024 | 659 | 0.140 |
Why?
|
| Endocrine System | 1 | 2018 | 112 | 0.140 |
Why?
|
| Inflammatory Breast Neoplasms | 1 | 2018 | 150 | 0.140 |
Why?
|
| Amyloidosis | 1 | 2024 | 877 | 0.130 |
Why?
|
| Eating | 1 | 2022 | 1539 | 0.130 |
Why?
|
| Endocrine System Diseases | 1 | 2018 | 247 | 0.120 |
Why?
|
| Glucose | 3 | 2022 | 4340 | 0.120 |
Why?
|
| Immunotherapy | 2 | 2022 | 4747 | 0.110 |
Why?
|
| Humans | 21 | 2024 | 766812 | 0.110 |
Why?
|
| Vaccination | 1 | 2024 | 3435 | 0.090 |
Why?
|
| Cardiomyopathies | 1 | 2024 | 2058 | 0.090 |
Why?
|
| Tomography, Emission-Computed | 1 | 2014 | 1006 | 0.090 |
Why?
|
| Male | 9 | 2024 | 364154 | 0.080 |
Why?
|
| Epithelial Cells | 1 | 2022 | 3698 | 0.080 |
Why?
|
| Stem Cell Transplantation | 1 | 2017 | 1600 | 0.080 |
Why?
|
| Lymphoma | 1 | 2017 | 1899 | 0.080 |
Why?
|
| Kidney Neoplasms | 1 | 2024 | 4282 | 0.070 |
Why?
|
| Huntington Disease | 1 | 2013 | 1147 | 0.070 |
Why?
|
| Retrospective Studies | 4 | 2022 | 81657 | 0.060 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2022 | 10384 | 0.060 |
Why?
|
| Aged | 5 | 2024 | 171344 | 0.060 |
Why?
|
| Middle Aged | 5 | 2024 | 223267 | 0.060 |
Why?
|
| Female | 7 | 2024 | 396532 | 0.060 |
Why?
|
| Octreotide | 1 | 2024 | 157 | 0.050 |
Why?
|
| Heterocyclic Compounds, 1-Ring | 1 | 2023 | 68 | 0.050 |
Why?
|
| Uracil-DNA Glycosidase | 1 | 2022 | 35 | 0.050 |
Why?
|
| Radioisotopes | 1 | 2024 | 509 | 0.050 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2014 | 2809 | 0.050 |
Why?
|
| Treatment Outcome | 3 | 2022 | 65286 | 0.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 11876 | 0.040 |
Why?
|
| Lung Neoplasms | 1 | 2024 | 13489 | 0.040 |
Why?
|
| DNA-Directed DNA Polymerase | 1 | 2022 | 481 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2017 | 9407 | 0.040 |
Why?
|
| Neoadjuvant Therapy | 2 | 2020 | 2902 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2017 | 36570 | 0.040 |
Why?
|
| Gonads | 1 | 2018 | 109 | 0.040 |
Why?
|
| Adult | 4 | 2022 | 223305 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2017 | 20710 | 0.030 |
Why?
|
| Adrenal Glands | 1 | 2018 | 556 | 0.030 |
Why?
|
| Pituitary Gland | 1 | 2018 | 635 | 0.030 |
Why?
|
| Antineoplastic Agents | 1 | 2018 | 13644 | 0.030 |
Why?
|
| Gene Deletion | 1 | 2022 | 2669 | 0.030 |
Why?
|
| Transplantation, Autologous | 1 | 2017 | 2127 | 0.030 |
Why?
|
| Lymph Node Excision | 1 | 2018 | 1267 | 0.030 |
Why?
|
| Islets of Langerhans | 1 | 2018 | 1350 | 0.020 |
Why?
|
| Thyroid Gland | 1 | 2018 | 1170 | 0.020 |
Why?
|
| Mastectomy | 1 | 2018 | 1861 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2018 | 3552 | 0.020 |
Why?
|
| Prognosis | 2 | 2022 | 29959 | 0.020 |
Why?
|
| Genome, Human | 1 | 2022 | 4443 | 0.020 |
Why?
|
| Risk | 1 | 2018 | 9602 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2023 | 14762 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2018 | 10101 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2022 | 17089 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2017 | 39312 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2020 | 59548 | 0.010 |
Why?
|
| United States | 1 | 2023 | 72945 | 0.010 |
Why?
|
| Child | 1 | 2013 | 80670 | 0.000 |
Why?
|